![]() Currently, we are determining if 15-PGDH levels can either identify individuals at increased CRC risk, or individuals who will respond to aspirin chemoprevention. Some of our achievements to date include: a) demonstrating that colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention, thus suggesting 15-PGDH represents an independent target for modulation by candidate colon tumor chemopreventive agents b) Identifying germline genetic variants in the 15-PGDH pathway that reduce colon 15-PGDH expression or function and are associated with increased CRC risk c) Discovering that patients with low 15-PGDH levels are resistant to the chemopreventive effects of celecoxib and aspirin and d) a co-first author paper published in Science discovering that 15-PGDH regulates tissue stem cell proliferation following tissue damage in the colon, which may have applications as a novel therapy the treatment of IBD. Current studies in the laboratory focus on two areas of translational research concerning 15-Hydroxyprostaglandin Dehydrogenase (15-PGDH) and Cell Migration-Inducing Hyaluronan Binding Protein (CEMIP): determining the utility of 15-PGDH and CEMIP as CRC biomarkers, and as novel therapeutic targets for treatment of CRC and/or inflammatory bowel disease (IBD). ![]() My research career has focused on understanding the mechanisms of colorectal cancer (CRC) initiation and progression as well as translational research of CRC. Opportunities for Pilot Projects to Support Multi-Investigator Grants.Adolescent and Young Adult Cancer Research Awards.Hematopoietic Biorepository and Cellular Therapy.Athymic Animal & Preclinical Therapeutics.Great Lakes Breast Cancer Research Symposium.Cancer-focused Summer Undergraduate Research (CanSUR).Clinical Oncology Research Career Development Program. ![]() HIV-associated Lung Malignancy Research Center.GI Specialized Program of Research Excellence (SPORE).Cleveland African American Prostate Cancer Project (CAAPP).Location: Boston University Medical Campus, 72 East Concord Street, L110, Medical School Building 1st Floor 17th Annual J. Fernandez present at this year’s Fink Memorial Lecture.ĭate & Time: Tuesday, Decem8:15 – 9:15 AM The Boston University School of Medicine is proud to have Dr. Fernandez’s achievements, please click here to see his bio. He is currently the Editor-In-Chief of Parkinsonism and Related Disorders, and has served on the editorial board of Movement Disorders and is currently an editorial board member of the American Journal of Clinical Neurology, European Neurological Journal, Journal of Clinical Movement Disorders, and Clinical Neuropharmacology. He has written a dozen books and has published 50 book chapters. He is the holder of the James and Constance Brown Family Endowed Chair in Movement Disorders and is an internationally recognized expert in movement disorders who has been voted one of the Best Doctors in America by his peers.Īn active and productive researcher, he has initiated or participated in over 100 clinical trials and has published his findings in well over 300 articles and abstracts on Parkinson’s disease, DBS, behavioral and non-motor features of PD, cervical dystonia, blepharospasm, and other movement disorders. Stephen Fink, MD, PhD Memorial lecture.ĭr Fernandez is Professor of Medicine (Neurology) at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University and Chair/Director of the Center for Neurological Restoration at Cleveland Clinic in Cleveland, Ohio. Fernandez, MD, will present this year’s J. Fernandez, MD to Present at Boston University Medical Campus Stephen Fink, MD, PhD Memorial Lecture to Take Place DecemHubert H.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |